Navigation Links
Industry-funded Breast Cancer Trials More Likely to Yield Positive Results

Industry-funded studies of breast cancer therapies are more likely to report positive results than non-pharmaceutical funded studies//, researchers from the University of North Carolina at Chapel Hill and the Dana Farber Cancer Institute have found. In addition, significant differences exist in the design and nature of clinical trials supported by the pharmaceutical industry compared to trials without industry involvement.

Published online today in Cancer, the journal of the American Cancer Society, the study explores the impact of pharmaceutical-company involvement on breast cancer clinical trial design and outcome. Drug-industry investment in research now exceeds the operating budget of the National Institutes of Health and previous studies have examined the impact on other areas of clinical medicine, but not breast cancer.

“Our study shines a flashlight on the issue of the rising role and potential impact of the pharmaceutical industry on breast cancer research and highlights important questions that need to be addressed through further research,” said Dr. Jeffrey Peppercorn, assistant professor of medicine in UNC School of Medicine’s division of hematology and oncology and a member of the UNC Lineberger Comprehensive Cancer Center.

“The significance of our study is not to say that the drug industry does anything wrong – they are excellent at developing new therapies, and there are many recent examples in breast cancer research. But if more and more research is funded by drug companies, then the limited amount of funding coming from other sources may need to be directed to address other questions,” Peppercorn said.

The researchers reviewed all breast cancer clinical trials published in 10 English-language medical journals in the years 1993, 1998 and 2003. They focused their formal statistical analysis on the 2003 trials because the identification of industry funded or non-industry funded research was likely more ac curate due to more stringent disclosure guidelines than earlier periods.

Trials with industry involvement were more likely than non-industry studies to use a single-arm study design, without a comparison group. This isn’t surprising, Peppercorn notes, because these studies are a key step in drug development.

In 2003, 57 percent of studies reported pharmaceutical involvement. Of these, 66 percent were single-arm studies. Only 33 percent of non-industry studies used single-arm design.

The industry studies were also more likely to yield positive results; 84 percent of industry-supported studies showed positive results, compared with 54 percent of non-industry studies.

“It’s been seen again and again in various branches of clinical medicine that studies that involve pharmaceutical industry sponsorship are more likely to have positive outcomes,” Peppercorn said. “It’s not fair to say at this point that it’s necessarily related to biased interpretation of results.” For instance, another explanation could be that industry makes smarter or safer choices about what drugs are brought to trial.

However, as industry funding becomes an increasingly dominant source of research funding, clinical questions that aren’t directly related to drug development may be neglected, Peppercorn said. Such questions include the optimal duration for giving a medication or whether certain groups of patients benefit from a medication more than others, he said.

Source-Nwswise
SRM
'"/>




Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Breast cancer treatment to be determined by gene test
3. Breast Feeding prevents obesity later on in life
4. Breast milk is essential
5. Breast Cancer Surgery Causes Psychological problems
6. Breast cancer evidence
7. Letrozole Beats Tamoxifen in Breast Cancer Therapy
8. Breast screening among diabetic women
9. Breast feeding can alter hormones
10. Diet, Sunlight connected to Breast Cancer Risk
11. Additional Radiotheraphy for Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... ... 20, 2017 , ... Announced that Clear Global ... services market) has entered into an agreement on September 1, 2017 with The ... is the first private Dental School to launch an online, accredited Post Graduate ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... gather for the National Athletic Trainers’ Association Annual Clinical Symposium and Expo. New ... It is also when Athletic Trainers are acknowledged by their peers with accolades ...
(Date:9/20/2017)... ... 2017 , ... Five consumer packaged goods (CPG) products were selected by the ... Nopavera Plus was named to the short list in the Specialty Supplements ... during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay Bay Resort ...
(Date:9/20/2017)... Eugene, OR (PRWEB) , ... September 20, 2017 , ... ... OSHA 10- and 30-Hour and HAZWOPER 8-, 24- and 40-Hour courses from now until ... , In addition to offering these discounted prices to all businesses and government ...
(Date:9/20/2017)... ... ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: A Bible-inspired ... the creation of published author, Bill Miller. Bill Miller has a unique ... than a decade of addiction to prescription drugs. He has a Bachelor ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
Breaking Medicine Technology: